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Summary
Background: Chronic constipation affects approximately 17% of the population
worldwide and remains an important unmet need since patients are often dissatis-
fied with treatment. Kiwifruit may offer an alternative to traditional laxatives and
have been shown to increase stool volume, frequency and improve consistency.
Aims: Using non‐invasive MRI techniques, we assessed the effect of ingestion of
kiwifruit on fluid distribution in the intestines and bowel function.
Methods: Two period crossover trial of kiwifruit vs control in healthy adults. Inter-
vention: two kiwifruits twice daily vs isocaloric control (maltodextrin) twice daily,
consumed for a total of 3 days. Subjects underwent MRI scanning fasted and at
hourly intervals for 7 hours on the third day. Primary outcome: T1 relaxation time
of ascending colon (T1AC) using MRI. Secondary outcomes: Small bowel water con-
tent (SBWC), colonic volume, gut transit time, T1 of descending colon, stool fre-
quency and form.
Results: Fourteen volunteers completed the study. T1AC was higher after kiwifruit
ingestion (P = 0.029) during the second half of the day (when meal residue would
be expected to reach the AC, AUC T1 T240-420 minutes; mean (SD) 137 (39)
s*minute with kiwifruit versus 108 (40) s*minute with control. SBWC (P < 0.001),
colon volumes (P = 0.004), as well as stool frequency (1.46 ± 0.66 with kiwifruit vs
1.14 ± 0.46 stools per day with control; P = 0.034) and stool form score (Bristol
Stool Chart score 4.1 (0.9) with kiwifruit versus 3.4 (0.7) with control; P = 0.011)
were markedly increased in participants consuming kiwifruit compared to control.
Conclusion: Consumption of kiwifruit in healthy volunteers increases water reten-
tion in the small bowel and ascending colon and increases total colonic volume. The
data may explain the observed increase in stool frequency and looser stool consis-
tencies, suggesting that kiwifruit could be used as a dietary alternative to laxatives
in mild constipation.
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1 | INTRODUCTION
Chronic constipation affects approximately 17% of the population
worldwide1 and its management remains an important unmet need
since patients are often dissatisfied with treatment.2 Current stimu-
lant or osmotic laxatives are successful in increasing stool frequency3
but are often associated with diarrhoea, bloating, cramps and
abdominal discomfort.4 Furthermore, such powerful treatments taken
intermittently may result in alternation between diarrhoea and no
stools, this is both inconvenient for the patient and potentially dis-
turbs the microbiota with uncertain consequences.5 Many patients
including those with mild symptoms who do not seek health care
would benefit from a less powerful treatment which could be taken
daily producing more regular stools of normal consistency.
Kiwifruit offer such an alternative and, in two open label and
one randomised placebo controlled trials, have been shown to
increase stool volume and frequency in patients with constipation.6–
8 The mode of action remains unclear as kiwifruit have many poten-
tially active ingredients.9
Kiwifruit are the berry of the Actinidia vine and there are two vari-
eties that are widely commercially available. These are the ‘Hayward’ or
green variety (Actinidia deliciosa) (marketed as Zespri® Green) and
“Zesy002” or gold variety (Actinidia chinensis) (marketed as Zespri® Sun-
Gold).
The fruit are nutrient‐dense and are high in vitamins C, E, K, and
in micronutrients potassium, folate, phytochemicals and carotenoids,
as well as in fibre.10
A dose of two Kiwifruit weighing 300 g contains approximately
12 g fructose, 12 g glucose and 9 g of dietary fibre. The fibre comes
primarily from the plant cell walls and is a mixture of soluble (one
third) and insoluble fibre (two thirds). The soluble fibre is pectic
polysaccharides and the insoluble fibre is cellulose and hemicellu-
lose.11 Pig studies showed that while the soluble component of kiwi-
fruit fibre is well digested in the small bowel, the insoluble
component passes largely intact into the colon.12
Kiwifruit cell walls have a large swelling and water retention
capacity both before and after digestion and in vitro tests (which
involve suspension in 250 mL of water and allowing to settle over-
night) found that it swells to over three times its original volume for
both green and gold kiwifruit.11 This swelling is around 1.5 times
that of psyllium, a commonly used laxative, and more than six times
that of apple fibre. The water retention capacity of the fibre,
defined as the amount of water which remains after centrifugation
of kiwifruit pulp suspended in water, was around 12‐13 g of water
per gram of insoluble fibre. Both this swelling and water retention
are high compared to other readily available forms of dietary fibre
such as apple, orange, wheat bran and sugar beet fibre.11
Soluble fibre is a proven laxative,13 softening stool and increasing
stool frequency. Early studies in ileostomy patients showed that psyllium
increases ileal flow14 but until recently its mode of action in the intact
colon was unclear. However, recently we have shown using novel non‐in-
vasive MRI techniques that psyllium 3.5 g taken three times daily
substantially increases small bowel water content (SBWC) in healthy vol-
unteers, retaining fluid in the small bowel. This increases the effect of the
gastro‐ileal response to eating which propels the retained fluid from the
ileum to the ascending colon immediately after eating a 1000 kcal meal.15
This is associated with an increase in colonic volume and water content.
Kiwifruit appear clinically to be as effective as ispaghula as shown in a
recent multi‐centre trial in Japan, Italy and New Zealand of 178 partici-
pants (n = 61 healthy, n = 57 FC and n = 60 IBS‐C). The effects of
4 weeks of kiwifruit (2 per day) and psyllium (7.5 g/day) were comparable,
with an increase of 2.1 complete spontaneous bowel movements per
week in the kiwifruit arm compared to 0.92 per week with psyllium com-
pared to baseline.16
Kiwifruit also contains insoluble fibre, which in the form of 15 g
bran has also been demonstrated to increase post‐prandial small
bowel water content17 and accelerate small bowel transit.18
Until recently, defining the site of action of kiwifruit at the level of
the small bowel and colon would require either invasive intubation
studies or the study of ileostomists whose physiology may well differ
significantly from the target population of healthy individuals. Using
recently developed and validated novel non‐invasive MRI techniques,
we have assessed transit and fluid distribution in the small intestine as
well as colonic fluid and volume19–22 in order to define the mecha-
nisms behind the known laxative effects of kiwifruit consumption. We
hypothesised that consuming kiwifruit would combine the effects of
both soluble and insoluble fibre, increasing the water content of small
and large intestine contents in healthy volunteers.
2 | METHODS
2.1 | Study design
This study was a two period, two treatment crossover study with
randomisation of treatment order. The study protocol was approved
by the University of Nottingham Medical School Ethics Committee
(Ref. A200317) and all volunteers gave written informed consent.
The study was carried out according to Good Clinical Practice as
defined by the Declaration of Helsinki. The study was registered on
clinicaltrials.gov, reference: NCT03303417.
2.2 | Study participants
Adult participants (aged 18‐65), able to give consent and scoring <2
on the 15 individual items (ie <15/45 total) of the Gastrointestinal
Symptom Rating Scale23 were recruited. Exclusion criteria were exist-
ing GI disorder or major GI surgery, inability to cease medication
affecting GI transit or motility, known intolerance of kiwifruit, con-
traindication to MRI scanning or lifestyle factors likely to disrupt gut
function or compliance with the protocol such as night shift working.
2.3 | Test products and meals
Test product was either two large and ready to eat green variety
kiwifruits without skins (approximate weight 150 g per kiwifruit)
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eaten twice per day or calorie matched control drink (28 g maltodex-
trin, average degree of polymerisation = 5, in 250 mL water provid-
ing 120 kcal and estimated osmolality of 124 mosmol/L). These were
consumed for 48 hours prior to the study day and on the scanning
day (12 kiwifruit/6 drinks total).
On the study day (see Figure 1 for an overview), participants
were fed two standard meals that we have used in previous stud-
ies.17 Meal A consisted of 220 g creamed rice pudding (Sainsbury's,
London, UK), 34 g seedless raspberry jam (Sainsbury's) and a glass of
100 mL pure orange juice from concentrate (Sainsbury's), providing
331 kcal. Meal B consisted of 400 g microwaveable macaroni cheese
ready meal (Sainsbury's), 100 g cheesecake slice (Sainsbury's) and
250 mL bottled still water, providing a total of 1007 kcal.
2.4 | Study day protocol
Consent, screening and enrolment took place at the Nottingham
Digestive Diseases Biomedical Research Unit, Nottingham. All subse-
quent study visits took place at the Sir Peter Mansfield Imaging Cen-
tre (SPMIC), University of Nottingham. Subjects visited the Imaging
Centre on two separate occasions, with at least 2 weeks between
each visit to minimise any carryover effect. Subjects were asked to
abstain from alcohol, caffeine and strenuous exercise for 18 hours
before the visit and did not eat after 8 PM on the evening before-
hand. The day before the scan they ingested five MRI marker pills at
9 AM, which were imaged 24 hours later at the beginning of the
study day. Ingestion was confirmed by a time‐stamped video. The
marker pills, which were developed in‐house, are inert capsules con-
taining the MRI contrast agent gadolinium, making the pills clearly
visible on the MR scan. Each pill is allocated a score based on its
position in the colon and a weighted average position score calcu-
lated as previously described.20 The same publication showed that
this score correlates well with transit time in hours as measured
using the well‐established radio‐opaque marker test.24
On the day of the visit, subjects fasted before attendance, with
the exception of sips of water with essential medicines. On arrival
they underwent a baseline MRI scan. They were then given 10 min-
utes to consume the test product. Thirty minutes later they con-
sumed test Meal A followed by another MRI Scan (Time = 0). They
then underwent hourly scanning for 7 hours (T = 0‐420). They had a
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second dose of test product immediately before the scan at T180 to
simulate the effect of two doses daily, giving time to see any effect
before the final Meal B between T = 360 and T = 420 (Figure 1).
Background diet was not controlled other than the instructions
given for the day before and during the MRI day; however, partici-
pants were asked to remain on their normal diet and not eat any
other kiwifruit during the study period (except those provided by
the study team).
2.5 | Questionnaires
Participants were asked to keep a diary of symptoms (abdominal pain,
nausea, bloating, gas estimated on a scale of 0‐3: none, mild, moderate,
severe) and bowel habit (frequency and form according to Bristol stool
form chart) during the week of the study day—this included the 2 days
prior to the consumption of the test product, the 3 days consuming
(including study day) and 2 days after this. Data were analysed for
kiwifruit or control on days 3‐6 of the respective study arm.
2.6 | MRI protocol
Imaging was carried out on a fully research‐dedicated 3.0 T Philips
Achieva scanner (Best, The Netherlands). Subjects were positioned
supine in the scanner with a parallel imaging SENSE XL‐Torso receiver
coil wrapped around the abdomen. Different imaging sequences were
used to optimally image the different regions of the gut as follows.
1. A high resolution balanced gradient echo sequence to acquire
sagittal images of the contents of the ascending colon, eight
slices 5 mm thick, 0.58 mm gap was acquired to include the
entire ascending colon. This was repeated for the descending
colon.
2. The longitudinal relaxation time T1 was measured in the ascend-
ing colon and separately in the descending colon, using a single
slice inversion recovery balanced turbo field echo sequence with
a preparatory 180° inversion pulse applied before acquiring the
imaging data. The slice for the T1 is chosen from the high resolu-
tion images and is chosen as the slice which provides the best
cross‐section through the colonic segment maximising the colonic
content to sample. The parameters for this sequence were a field
of view of 400 (HF) × 280 (AP) mm; 7 mm slice thickness; half
Fourier acquisition; 256 × 256 matrix; repetition time/echo time
2.4/1.2 milliseconds; flip angle 45°. Data were acquired from
eight different inversion times (TI; time between inversion pulse
and imaging pulses) ranging from 0.05 to 4.95 seconds.21 There
was a 15 second gap between each acquisition to allow the sys-
tem to return to equilibrium.
3. A single shot, fast spin echo sequence (rapid acquisition with
relaxation enhancement; effective echo time TE = 400 millisec-
onds) to acquire in a single breath‐hold, 20 coronal images with
in‐plane resolution interpolated to 0.78 mm × 0.78 mm and a
slice thickness of 7 mm, with no gap between slices (acquired
voxel size = 1.4 × 1.76 × 7 mm3), SENSE = 2.0. This sequence
yields high‐intensity signals from areas with freely mobile fluid
and little signal from body tissues and was used to measure small
bowel water content.17,19
4. Colonic volumes were assessed using a coronal 3D dual‐gradient
echo sequence (TE1 = 1.07 milliseconds, TE2 = 1.9 milliseconds,
repetition time = 3.0 milliseconds) and mDIXON readout.25 The
field of view at each station was 250 mm (HF) × 375 mm (LR) by
200 mm (AP) with acquired slice thickness 3.6 mm, interpolated
to 1.8 mm with a reconstruction matrix of 432. These two sets
of images were combined into a single image of matrix size 543
(HF) × 432 (LR) and 37 slices of thickness 5.4 mm and were used
to visualize the colonic anatomy. Four different image types are
produced from this acquisition, water only, fat only, fat and water
in‐phase and fat and water out‐of‐phase data. Slices were
acquired in two overlapping coronal stacks (30 mm overlap), each
acquired in a breath hold. Colonic volumes were measured manu-
ally as previously described.22 The water‐only images from this
sequence were also used to locate the position of the transit pills
within the GI tract.20
Data were all acquired on an expiration breath‐hold with dura-
tion between 13 and 24 seconds depending on the sequence, moni-
tored using a respiratory belt. Including set‐up and imaging, the
volunteers spent approximately 20 minutes inside the magnet for
every time point and the rest of the time sitting upright in an adja-
cent room.
2.7 | Outcomes
The primary outcome was longitudinal relaxation time (T1, an MRI
constant reflecting water mobility) of the chyme in the ascending
colon, this reflects the fluidity of the contents, with more fluid con-
tents having a longer T1 time for example, liver has a T1 of 750 mil-
liseconds while cerebrospinal fluid has a T1 of 4000 milliseconds at
3 T field strength. Secondary MRI outcomes were: T1 of descending
colon, SBWC, colonic volume, gut transit time as assessed by WAPS
at 24 hours and questionnaire‐based scores for symptoms and bowel
habit. Stool consistency was measured using the Bristol stool form
scale (ranges from 1 = hard lumpy stools to 7 = watery stools).
2.8 | Randomisation and blinding
The order of the test products was randomised using www.randomi
sation.com. Neither subjects nor researchers were blind to the meal
consumed on study days. All study data and images carried an
anonymising study ID number and MRI analysis were conducted
blind to the intervention.
2.9 | Power calculation
Our data15 with a standard laxative dose of psyllium 7 g three times
per day showed a change of the area under the curve of T1 vs time
from time 0 to time 360 minutes (T1 AUC 0‐360) of mean (SD) 88
4 | WILKINSON‐SMITH ET AL.
(55) seconds × minutes. Using these data, we calculated that n = 15
healthy volunteers will give us >90% power to detect a similar dif-
ference.
2.10 | Data analysis
The image data set from each subject and each time point was
stored on a password‐protected server and processed as previously
described using either software written in house in IDL (version 6.4;
Research Systems Inc, Boulder, CO, USA; for analysis of SBWC and
T1 relaxation times) by Dr Caroline Hoad at the SPMIC, or commer-
cial software (ANALYZE v.9, Biomedical Imaging Resources, Mayo
Clinic, Rochester, MN, USA; for analysis of colon volumes).19,21,22
2.11 | Statistical analysis
GRAPHPAD PRISM (v.7; San Diego, CA, USA) and SPSS (v.24; IBM;
Armonk, NY, USA) were used for statistical analysis of the data. We
assessed the changes over time and between treatments using a
two‐way analysis of variance (ANOVA) test. Normal distribution of
data was determined using the Shapiro‐Wilk test. Within each scan-
ning time point, data were then compared with a paired t‐test, for
parametric data, or with a paired Wilcoxon test, for nonparametric
data. P = 0.05 was used as the threshold for statistically significant
outcomes. When data were ordinal (stool frequency, stool form
score), a Wilcoxon test (kiwifruit compared to control) or Friedman
ANOVA (kiwifruit compared to control and baseline) was carried out.
For the outcomes recorded in the questionnaires over several days
(stool frequency, stool form, symptoms), the data within each period
(kiwifruit and control) were summarised by their median for each
participant, before applying the appropriate tests. Data are displayed
as median and interquartile range.
3 | RESULTS
Sixteen participants were recruited but two dropped out after a sin-
gle visit due to unexpected work commitments so 14 volunteers
completed the study. Of these 14, six were female, eight were male
with a median age of 26 ± 4 (range 21‐33) years and a body mass
index of 23 ± 4 (range 18‐30) kg/m2. Median score was 0.5 (range 0‐
4) on Gastrointestinal Symptom Rating Scale. The study procedures
were well tolerated by the subjects.
3.1 | T1 relaxation time of chyme in the ascending
colon
The primary outcome was defined as the area under the curve for
T1 relaxation time measured in the ascending colon over the time
from baseline until the end of the study day (T420), comprising of
eight hourly scans, and was increased in the kiwifruit arm however
did not reach significance (P = 0.056, Table 1). As individual data
points measured at each scan, T1 relaxation time is not different as
analysed by two‐way ANOVA, P = 0.75 (Appendix S1).
Analysing the T1 relaxation time data further, when the area
under the curve was measured from the time point when the first
meal and treatment products start reaching the colon, T240‐T420,
this showed a statistically significant increase of T1 relaxation time
from the control to the kiwifruit arm of the study (+27%, P = 0.029,
Table 1 and Figure 2).
3.2 | T1 relaxation time in the descending colon
In the descending colon measuring T1 relaxation time was challeng-
ing, as the descending colon was sometimes empty, therefore some
data sets were excluded from the analysis (n = 9 for control and
n = 12 for kiwifruit). There was no difference between the kiwifruit
and the control arms of the study, regardless whether the area under
the curves was considered over the whole day (P = 0.3, Table 1),
over the later time points (T240‐T420, P = 0.4, Table 1) or when
each time point was considered individually (two‐way ANOVA
P = 1.0, Appendix S1).
3.3 | Small bowel water content
Kiwifruit markedly increased SBWC, both when expressed as area
under the curve (P = 6 × 10−6) (Table 1), and when measured
throughout the day (two‐way ANOVA, overall P = 3 × 10−32, differ-
ence between treatment products P = 2 × 10−22, difference
between time points P = 2 × 10−18, interaction P = 8 × 10−7).
TABLE 1 Data for MRI variables measured as AUC of hourly scans. AUC expressed as a function of time (SBWC and colon volume ml.min
or T1 seconds.minutes)
MRI endpoint Kiwifruit Control P‐value
AUC T1 AC (seconds.minutes) Baseline‐420 356 ± 109 291 ± 110 0.056
AUC T1 AC (seconds.minutes) T240‐420 137 ± 39 108 ± 40 0.029*
AUC T1 DC (seconds.minutes) Baseline‐420 216 ± 120 203 ± 114 0.3
AUC T1 DC (seconds.minutes) T240‐420 96 ± 50 87 ± 52 0.4
AUC SBWC (mL.minutes) Baseline‐420 85 530 ± 34 923 35 023 ± 15 557 6 × 10−6*
AUC colon volume (ml.min) Baseline‐420 283 583 ± 59 402 243 182 ± 46 682 0.004*
AC, ascending colon; AUC, area under the curve; DC, descending colon; SBWC, small bowel water content; T1, T1 relaxation time.
Data are expressed as mean ± SD.
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SBWC was increased at all time points except for baseline, when
participants arrived fasted (paired tests, P < 0.05 indicated by aster-
isks, Figure 3, Appendix S1).
3.4 | Regional and total colon volumes
As Table 1 shows, area under the curve from baseline‐T420 for the
total colon volume is increased in the kiwifruit arm of the study
(P = 0.004, see Figure 4 and Table 1), due to an increase in ascend-
ing colon volume (P = 0.003). Both transverse and descending colon
volume AUCs were similar between the groups.
Two‐way ANOVA showed significant effects of treatment but
not time for total colon volumes and ascending colon volumes,
AUCbase‐420 minutes of total colon volumes (overall P = 0.011, differ-
ence between treatment products P = 2×10−7, difference between
hourly time points P = 0.8, interaction P = 1.0) and AUCbase‐420 minutes
of ascending colon volumes (overall P = 0.035, difference between
treatment products P = 2 × 10−6, difference between time points
P = 0.8, interaction P = 1.0). However, ANOVA for transverse and
descending colon volumes showed no significant differences (P = 0.9
and P = 0.148 respectively).
Total colon volume was increased at all time points except base-
line (paired tests, P < 0.05). Similarly, volumes of the ascending
colon were increased at most time points (except baseline and
T180), whereas transverse and descending colon volumes were only
significantly increased at a few time points, which for the descending
colon tended to be towards the end of the scanning session
(Appendix S1 and S2).
3.5 | Whole gut transit
Whole gut transit was similar on both arms of the study with
weighted average position score (kiwifruit median score 0.8 [0‐1.4
IQR], control median score 1.0 [0.5‐3.1 IQR], P = 0.11).
3.6 | Stool diary and symptom questionnaire
Daily stool frequency was significantly increased during the kiwifruit
arm (defined as days when the treatment product is consumed plus
the following day, ie days 3‐6, indicated by the shaded area in Fig-
ure 1) compared to the control arm (1.46 ± 0.66 vs 1.14 ± 0.46
stools per day; P = 0.034 Wilcoxon; Figure 5A).
The consistency scores of stools were different between groups
(P = 0.049, Figure 5B), with higher scores (softer/more watery stools)
in the kiwifruit arm compared to control (P = 0.011).
There was no significant difference in the scores for any adverse
symptoms between the kiwifruit consumption, control consumption
and baseline (Appendix S3). As both kiwifruit and the control mal-
todextrin drink were well tolerated, participants reported few
instances of these symptoms, with no symptom reported to be
higher in severity than level 2 (moderate).
4 | DISCUSSION
This study aimed to use MRI techniques to identify the mechanism
of action behind the therapeutic benefit seen from kiwifruit in previ-
ous studies. We hypothesised that some of the physicochemical
properties of kiwifruit would increase intestinal water, and we have
found this to be the case.
Colonic water content, reflected by T1 relaxation time, showed
some increase in the ascending colon. This is likely due to water
trapping by the fruit fibre in the small intestine. The timing of the
increase in colonic water content in the second half of the study day
is in accordance with when the meal contents would be predicted to
reach the caecum.
In the descending colon measuring T1 relaxation time was chal-
lenging, as the descending colon was sometimes empty. There was
no difference in T1 found here and the values were generally lower
than those in the ascending colon. This is as previously reported15
and in keeping with the function of the colon in progressively dehy-
drating colonic contents as they move distally.
T1 AC AUC T240-T420
T1 AC AUC Baseline-T420
Control
100
0
50
200
250
T1
 re
la
xa
tio
n 
tim
e 
(s*
mi
n)
150
0
400
600
T1
 re
la
xa
tio
n 
tim
e 
(s*
mi
n)
200
(A)
(B)
Kiwi
+27%
P = 0.029
(+23%)
P = 0.056
Control Kiwi
F IGURE 2 T1 relaxation time in the ascending colon expressed
as area under the curve from baseline until the end of the scan day
(Baseline‐T420, A); and from the time that the first meal is assumed
to have reached the ascending colon until the end of the scan day
(T240‐T420, B)
6 | WILKINSON‐SMITH ET AL.
Regarding the SBWC, the pattern seen on the control arm was
similar to that observed previously17,26 with an initial drop in content
likely to reflect the rapid absorption of water with the glucose, fruc-
tose and sucrose molecules in the orange juice in the test meal, fol-
lowed by a later rise due to intestinal and pancreatic secretions
accompanying the gastric emptying of the solid phase of the test
meal into the small bowel. The maltodextrin did not appear to
increase SBWC over baseline despite being given with 250 ml of
water behaving as we have observed with pure glucose17 suggesting
it was rapidly digested. In contrast, the water content on the kiwi-
fruit arm rose initially with two peaks seen to coincide with the
ingestion of the kiwifruit doses. This suggests kiwifruit impairs water
absorption as it does for glucose absorption as previously demon-
strated by reduced post‐prandial hyperglycaemia.27 The second peak
was greater than the first—which may reflect retention of the initial
fibre within the small bowel with additional water trapping by the
second dose. The larger increase after the second dose may be also
due to the fact that the sugars in Meal A may have enhanced water
absorption immediately after ingestion of the first dose.
There was no significant difference in SBWC at the fasting time
point despite pre‐dosing for 2 days, which suggests that the effect
of the kiwifruit disappears overnight when the small bowel contents
are emptied into the colon by the migrating motor complexes which
occur during overnight fasting.28
Colonic volumes were increased by kiwifruit ingestion which may
reflect the increased volume of water arriving in the colon. Although
flow through the colon is not uniform, colonic volumes can be
approximated from the formula: Volume = flow (24 hours stool
excretion) × transit time. The rise in colonic volumes despite
unchanged transit time implies therefore an increase in 24‐hour stool
excretion in keeping with the more frequent passage of looser stools
we observed. It is worth noting that while the colon volume average
as assessed by the AUC 0‐420 minutes throughout the study day
rose by 16% this is much less that the 50% increase in total colonic
volume we previously reported after 10.5 of psyllium daily.15 This
may suggest that kiwifruit has prokinetic effects in addition to simple
water trapping and hence less colonic distension when compared to
ispaghula. Whether this translates into less bloating would require a
head to head direct comparison study.
Acceleration of transit, when compared to psyllium (7.5 g/day),
by two kiwifruit daily was observed in the Japanese arm29 of the
multicentre study already described above16. The fact that we did
not observe a significantly accelerated transit time may in part be
due to a ‘floor effect’ in this healthy volunteer population in whom
transit, as we have previously observed, is relatively fast at 28 hours
(IQR 4‐50) with some subjects with a low or zero weighted average
position score and hence difficult to demonstrate further acclera-
tion.20 We did observe that there was a higher proportion of
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subjects who had expelled all the marker pills at the 24‐hour mark
(giving a score of 0) in the kiwifruit arm (six participants) compared
to control (two participants). Similar findings were seen in another of
our recent studies assessing the effect of psyllium on transit in
which transit times were not seen to be significantly increased in
healthy volunteers as most markers had passed to the rectosigmoid
colon or had been expelled at 24 hours, whereas a significant
increase in speed was seen in participants with constipation whose
baseline transit was slower.15
Despite using healthy volunteers rather than constipated
patients, the change in bowel habit (increased frequency with a nor-
mal stool form) and low side‐effect profile are similar to what has
been seen in previous patient studies.6–8
4.1 | Limitations
This mechanistic study was limited by small sample size which was
exacerbated by some participants’ withdrawal from the study. Our
subjects were young adults so caution is needed in extrapolating our
results to the elderly. However, this data will serve as a basis for
power calculations for future MRI studies of digestive function.
We also did not control any other aspects of diet—for example,
limiting any other fruit consumption (beyond asking not to eat kiwi-
fruit in the control week) or other sources of fibres. We gave two
meals on the study day to simulate how kiwifruit are normally con-
sumed as part of a mixed diet. Both have been used in previous
studies, so their effect is known, however the nutrients they contain
may have interacted with the digestion of the kiwifruit and vice
versa.
The kiwifruit we used were top quality and somewhat larger
than the average on sale at present. Furthermore, the dose of two
kiwifruit twice daily was large compared to normal consumption but
ensured a clear mechanistic result in the limited intervention time
with the small numbers it was feasible to scan. The clinical trials
show that more reasonable doses that is, two daily are also clinically
effective.6–8,16 The maltodextrin acted as a control for calorie con-
tent but did not control for other aspects like chewing and saliva-
tion.
5 | FUTURE WORK AND CONCLUSIONS
Future work may want to look at whether other fruits have similar
mechanisms of action or whether these are unique to the kiwifruit.
Kiwifruit contain substantial amounts of the protease actinidin which
has the potential to activate protease‐activated receptors found on
enterocytes, lymphocytes and enteric nerves which have been
shown to play an important role in visceral sensitivity. Kiwifruit also
contain raphides (needle‐shaped calcium oxalate crystals found in
the tissues of kiwifruit). It is unclear whether these are all destroyed
in the acid gastric environment or whether some enter the small
bowel where they might stimulate water secretion. Whether
raphides or actinidin alter colonic absorption, secretion or motility
remains to be determined. The effect of the kiwifruit on the micro-
biota may also be another area worth studying in more detail since
preliminary studies show its consumption increases lactobacilli and
bifidobacteria.30
In conclusion, these MRI data suggest that consumption of kiwi-
fruit in healthy volunteers increases water content in the small
bowel and ascending colon, as well as an increase in colonic bulk.
These data are consistent with the observations of an increase in
stool frequency and looser stool consistencies, suggesting that kiwi-
fruit could be used as a dietary alternative to laxatives in mild consti-
pation.
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